LLY
Eli Lilly and Company
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
·Consolidated from 3 sources
{ "
{ "
Sources
This recap was generated by consolidating the public headlines below.
- Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss DataJul 23, 2026
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CJul 23, 2026
- Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its PipelineJul 23, 2026